Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$477.37 USD
+5.37 (1.14%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $477.37 0.00 (0.00%) 5:36 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$477.37 USD
+5.37 (1.14%)
Updated Aug 16, 2024 03:55 PM ET
After-Market: $477.37 0.00 (0.00%) 5:36 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
3 Big Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.
The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial
Top Stock Reports for Celgene, Sinopec & HSBC
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), Sinopec (SNP) and HSBC Holdings (HSBC).
Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
by Zacks Equity Research
Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M
by Zacks Equity Research
Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
by Ekta Bagri
Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $178.98 in the latest trading session, marking a +0.36% move from the prior day.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Moving Average Crossover Alert: Vertex Pharmaceuticals
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Surging Earnings Estimates Signal Upside for Vertex (VRTX) Stock
by Zacks Equity Research
Vertex (VRTX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Top Research Reports: Amazon, Caterpillar, Vertex & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 12 major stocks, including Amazon (AMZN), Caterpillar (CAT) and Vertex (VRTX).
Mergers & Acquisitions Take Center Stage in Biotech Industry
by Zacks Equity Research
Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.
Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up
by Zacks Equity Research
Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.
Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up
by Zacks Equity Research
Perrigo (PRGO) reports encouraging second-quarter 2019 results. The Rx segment recovers on strong new product sales.
Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports mixed second-quarter results. Revenues fall on reduced collaboration and contract revenues.
Is Vertex (VRTX) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Vertex (VRTX).
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View
by Zacks Equity Research
Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.
Proteostasis (PTI) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors will focus on the cystic fibrosis studies, when Proteostasis (PTI) reports second-quarter 2019 earnings.
Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 22.33% and 6.52%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?